Supplementary Table 1.

Reasons for excluding studies assessed for eligibility.

Author (year)	Study title	Reason for exclusion
Blundell et al, 2017	Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity	Gl adverse events were not reported
Wharton et al, 2023 step 5 study	Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5	Gl adverse events were not reported
Wharton et al, 2021	Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss	Non RCT study, Patients with type 2 DM were included
Enebo et al, 2021	Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2–4 mg for weight management: a randomised, controlled, phase 1b trial	Did not meet the eligibility criteria, both arms received semaglutide
Weghuber et al, 2023	Once-Weekly Semaglutide in Adolescents with Obesity	Patients with type 2 DM were included
Ghusn et al, 2022	Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity	Non RCT study, Patients with type 2 DM were included
Slomski et al, 2022	Tirzepatide Trial Demonstrates Substantial Weight Loss	Non RCT study
Hindson et al, 2022	Tirzepatide to treat obesity: phase III results	Non RCT study
Malhotra et al, 2024	Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial	Gl adverse events were not reported
Hankosky et al, 2023	Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial	Gl adverse events were not reported
Kauffman et al, 2022	In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk	Non RCT study
Wilkinson et al, 2023	Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity	Gl adverse events were not reported
Ikushima et al, 2018	Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects	Gl adverse events were not reported
Hjerpsted et a I, 2017	Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity	Gl adverse events were not reported
Mu et al, 2024	Efficacy and safety of once weekly semaglutide 2–4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial	Patients with type 2 DM were included
Kelly et a I, 2023	Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg	Patients with type 2 DM were included + Gl adverse events were not reported
McGowan et al, 2023	Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial	Gl adverse events were not reported
Snitker et al, 2022	Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial	Gl adverse events were not reported
Bjorner et al, 2023	The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1–4 obesity trials	Patients with type 2 DM were included
Kolotkin et al, 2023	Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight-and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial	Patients with type 2 DM were included